NETSCIENTIFIC PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 63 GBX | 0.00% |
|
0.00% | +5.00% |
| 04-15 | Netscientific's ProAxsis Secures Investment for Product Development | MT |
| 04-15 | NetScientific investee secures funding to develop product range | AN |
| Sales 2021 | 1.11M 1.38M 111M | Sales 2022 | 1M 1.25M 100M | Capitalization | 18.81M 23.49M 1.88B |
|---|---|---|---|---|---|
| Net income 2021 | -2M -2.5M -200M | Net income 2022 | -3M -3.75M -300M | EV / Sales 2021 | 17 x |
| Net cash position 2021 | 2.06M 2.57M 206M | Net Debt 2022 | 402K 502K 40.2M | EV / Sales 2022 | 19.1 x |
| P/E ratio 2021 |
-7.49
x | P/E ratio 2022 |
-5.79
x | Employees | 26 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 60.02% |
More Fundamentals
* Assessed data
More news
More press releases
| Current month | -5.97% | ||
| 1 month | -7.35% | ||
| 3 months | +4.13% | ||
| 6 months | +13.51% | ||
| Current year | +5.00% |
1 week
61.00
62.89
1 month
58.0069.20
Current year
56.0078.00
1 year
48.0082.00
3 years
42.22210.00
5 years
9.75210.00
10 years
9.752 150.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ilian Iliev
CEO | Chief Executive Officer | 48 | 13/10/19 |
Stephen Crowe
DFI | Director of Finance/CFO | - | 31/10/18 |
Edward Hooper
BRD | Director/Board Member | - | 06/06/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Spicer
CHM | Chairman | 59 | 30/05/23 |
| Director/Board Member | 59 | 08/12/22 | |
Ilian Iliev
CEO | Chief Executive Officer | 48 | 13/10/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 63 | 0.00% | 14,893 |
| 25/04/24 | 63 | 0.00% | 1,654 |
| 24/04/24 | 63 | 0.00% | 904 |
| 23/04/24 | 63 | 0.00% | 1,000 |
| 22/04/24 | 63 | 0.00% | 34,895 |
Delayed Quote London S.E., April 26, 2024 at 04:35 pm
More quotes
NetScientific plc is a United Kingdom-based deep tech and life sciences venture capital (VC) investment group with an international portfolio of innovative companies. The Company identifies, invests in, and builds high growth companies in the United Kingdom and internationally. It employs a capital-light investment approach, making use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital Limited. The Company secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a structure that can support a large portfolio. Its portfolio consists of a combination of direct investments and capital under advisory (CUA). The Company has about 24 portfolio companies with a focus on life sciences, technology, and sustainability. The Company's subsidiaries include EMV Capital Limited, Glycotest, Inc., and ProAxsis Limited, among others.
Calendar
25/09/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +5.00% | 18.79M | |
| +31.41% | 12.02B | |
| +14.40% | 3.06B | |
| +2.96% | 1.42B | |
| -8.46% | 1.22B | |
| +1.15% | 616M | |
| -10.84% | 579M | |
| +35.79% | 577M | |
| -4.17% | 492M | |
| +33.85% | 488M |
- Stock Market
- Equities
- NSCI Stock
